Tag: Business Wire

NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) announced today that, at the annual general meeting (the “Meeting”) of shareholders of the Company (“Shareholders”) that was held on Tuesday, September 20, 2022, all nine nominees for the board of directors of the Company were elected, the voting results of which are as follows:

Director	Number and percentage of common shares(1) of the Corporation (“Shares”) represented in person or by proxy and entitled to vote at the Meeting that were voted FOR	Number and percentage of Shares represented in person or by proxy and entitled to vote at the Meeting that were WITHHELD from voting
Nicholas Vita	115,340,138 (96.14%)	4,632,880 (3.86%)
Michael Abbott	112,854,970 (94.07%)	7,118,048 (5.93%)
Frank Savage	114,522,688 (95.46%)	5,450,330 (4.54%)
James A.C. Kennedy	118,891,321 (99.10%)	1,081,697 (0.90%)
Jonathan P. May	119,079,350 (99.26%)	893,668 (0.74%)
Jeff Clarke	119,069,317 (99.25%)	903,701 (0.75%)
Alison Worthington	119,308,625 (99.45%)	664,393 (0.55%)
Julie Hill	119,335,770 (99.47%)	637,248 (0.53%)
Philip Goldberg	116,870,341 (97.41%)	3,102,677 (2.59%)
Notes: (1) Assuming conversion of all proportionate voting shares into common shares.

Shareholders also approved the re-appointment of Davidson & Company LLP as auditor of the Company for the ensuing year and the authorization of directors to fix their remuneration.

Full details of the foregoing are contained in the Report of Voting Results for the Meeting which has been filed on SEDAR at www.sedar.com.

About Columbia Care Inc.

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions. Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, Amber and Platinum Label CBD. For more information on Columbia Care, please visit www.columbia.care.

Contacts

Investor Contact
Lee Ann Evans

Capital Markets

ir@col-care.com

Media Contact
Lindsay Wilson

Communications

+1.978.662.2038

media@col-care.com

LOS ANGELES–(BUSINESS WIRE)–#CaliforniaCannabis—Mari y Juana® Beverages Co. (“MJ”), a California-based cannabis-infused beverages brand that recently took home 1^st place in High Times 2022 SoCal Cannabis Cup – People’s Choice Edition for their ¡Piña! flavored soft drink today announced its exclusive partnership with Ginger, an e-commerce provider and last-mile delivery service in the ever-expanding direct-to-consumer (DTC) California cannabis market.

Knowing direct-to-consumer delivery in the cannabis space has quickly grown into a dominating revenue channel for businesses, MJ is expanding its revenue streams and availability of MJ branded products through one of the largest DTC providers on the West Coast.

“As a millennial I’ve known and grown with the experience of the dot-com era and seeing how e-commerce has been able to benefit both business and consumer. We are extremely delighted that with the support of Ginger we will be able to utilize tools currently available to substantially grow our business as we focus on strategic bulk selling directly to the end-user.

“As supportive as our retail partners are, stocking and selling 24-pack quantities of MJ beverages is an unnecessary burden and ask of them. The ability to transact larger purchases via our website directly to the customer is an added value offer by the MJ brand to the customer, to the retail store partner and to the overall cannabis-infused beverages category. Our target demographic usually has big families and throws big fiestas so this looks to be a promising win-win situation for all parties!” said Daniel Torres, Founder and CEO of Mari y Juana™ Beverages Co.

“We’re excited to have Mari y Juana on the list of innovative brands actively pursuing growth via this new and exciting channel. Their unique product line and story set the stage for new customers and Ginger is looking forward to helping turn them into loyal fans,” said Roie Edery, Founder and CEO of Ginger.

Beginning late September, consumers will be able to purchase Mari y Juana beverages in bulk directly via the DrinkMJ.com website.

About Mari y Juana® Beverages Co.

A subsidiary of Mari y Juana® Foods Co., founded in Los Angeles, CA in 2015, Mari y Juana® Beverages Co. was formed in October 2021 and has allowed the brand to evolve and partake in the ever-growing cannabis-infused beverages category creating a new path for itself and California cannabis consumers. While edibles were the Company’s initial focus, the beverage category offered an opportunity to further grow the brand equity. The mutual goal for both companies has always been to bring products to the California edible cannabis market that are indicative of Mexican culture and culinary traditions. The Company slogan is ‘Made in California of Mexican Descent™’. For more information visit www.DrinkMJ.com, email Hola@DrinkMJ.com, or check them out on Instagram.

About Ginger

Ginger is the only Direct-To-Consumer sales solution in California that directly connects brands to their loyal customer base. Ginger’s proprietary e-commerce and logistics technology is built specifically for cannabis brands that want to grow their sales, engage with customers, and tap into the exploding trend of DTC sales. With Ginger’s e-commerce technology, brands can offer next-day delivery and provide a custom-branded, ideal delivery experience. Ginger allows brands to nurture their loyalists and create new ones daily. Learn more at: www.gingercommerce.com.

Contacts

HJ-PR

hello@hj-pr.com
+1-424-385-1758

Efficacy data anticipated in Q4 of 2022

BALTIMORE, Md.–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.^® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, announced a dosing update on its fully-funded Phase 2 clinical trial of lead drug candidate MYMD-1^®, an orally available next-generation TNF-alpha inhibitor, as a therapy for chronic inflammation associated with sarcopenia and frailty.

To date, the trial has completed dosing for the second patient cohort. The Safety Review Committee has confirmed no safety or toxicity issues and has voted unanimously to escalate to the next higher dose and begin enrolling the next cohort.

“We are pleased with the good news that we will be progressing our Phase 2 trial into the next dosing cohort, given that MYMD-1 has been well-tolerated by participants to date,” said Chris Chapman, MD, President, Director and Chief Medical Officer of MyMD. “We continue to anticipate efficacy data later this year.”

The Phase 2 multi-center double-blind, placebo controlled, randomized study (NCT05283486) is currently ongoing to investigate the efficacy, tolerability and pharmacokinetics of MYMD-1 in the treatment of chronic inflammation associated with sarcopenia/frailty in participants aged 65 years or older.

About MyMD Pharmaceuticals

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. MyMD’s lead clinical candidate, MYMD-1®, is an orally available next-generation TNF-alpha inhibitor with the potential to transform the way that TNF-alpha based diseases are treated. MYMD-1®, with its small molecule design, improved safety profile and ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-alpha inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases. MYMD-1 has demonstrated the potential to slow the aging process and extend healthy lifespan. The company is evaluating MYMD-1® in Phase 2 studies for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications. MyMD’s second therapeutic candidate is Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times more potent a CB2 agonist (activator) than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown to have anti-inflammatory effects. For more information, visit www.mymd.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would” and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed by MyMD on March 31, 2022, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Contact:
Robert Schatz

(646) 421-9523

rschatz@mymd.com

Media Contact:
Mike Beyer

Sam Brown, Inc.

(312) 961-2502

MikeBeyer@sambrown.com

OxyCom’s Cooling Technology Complies with ESG Initiatives

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–O2 Natural Air LLC d/b/a/ OxyCom N.A. www.oxycom.org (“O2” or the “Company”) announced today that it has entered into an exclusive distribution agreement with patented two-stage commercial climate control technology manufacturer, OxyCom Fresh Air BV.

OxyCom Fresh Air BV is headquartered in the Netherlands, founded in 2002 as pioneers and designers of highly innovative “natural cooling systems” with one goal in mind, to reduce the global ecological footprint required for cooling, ventilating, and heating for commercial applications.

Adiabatic cooling is the process of reducing heat through a change in air pressure caused by volume expansion. “It is one of the most natural cooling methods in the market, consuming 90% less energy,” said Victor E. Mancebo. The World Economic Forum states that conventional air conditioning accounts for 40% of all global carbon emissions.

“We are excited to partner and formally introduce the patented OXYCOM commercial climate control technology in North America,” said Mancebo, Partner of OxyCom N.A. “The OXYCOM two-stage technology can serve numerous industries, inclusive of cannabis facilities, shopping centers, distribution centers, food processors, data centers, offices, warehouses, manufacturing, supermarkets, etc. As leaders in our industries, we have a social responsibility to reduce our carbon footprint, and partake in the ESG global movement, and OXYCOM is a viable and economic solution,” states Mancebo.

“Partnering with OxyCom N.A. is an excellent step in expanding OXYCOM’s continent distribution reach,” said Barry Leuverman, Director, OxyCom Fresh Air BV. “We look forward to working alongside with Mr. Mancebo, a strong leader in the cannabis industry. The North American market is pivotal for our growing success.”

For further OXYCOM inquiries, please connect with our specialized team at www.oxycom.org or sales@oxycom.org or 1 (800) 807-3683.

About OxyCom N.A.

OxyCom N.A. is an exclusive distributor of OXYCOM two-stage technologies in the North American continent. OxyCom N.A. is committed in helping companies reduce their global carbon footprint and assist with their Environmental, Social, and Corporate Governance (ESG) initiatives while controlling their operating climate environment. OxyCom N.A. provides a trusted and patented climate control technology focused on maximizing returns for our clients. For more information, please visit: www.oxycom.org

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contacts

Victor E. Mancebo

Partner

(800) 807-3683

Victor@OxyCom.org

DUBLIN–(BUSINESS WIRE)–The “Cannabis Beverages – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Cannabis Beverages Market to Reach US$2 Billion by the Year 2026

Amid the COVID-19 crisis, the global market for Cannabis Beverages estimated at US$1 Billion in the year 2022, is projected to reach a revised size of US$2 Billion by 2026, growing at a CAGR of 16.9% over the analysis period.

Cannabis has been gaining considerable popularity globally. Its use for recreational purposes (factoring in the illegal usage) is much higher in comparison to its medicinal use. The market is anticipated to be on a growth path due to the growing cannabis demand in the mainstream market.

The changing legal status of marijuana in a growing number of countries worldwide, including several US states, is attracting more and more food and drink companies to the vibrant cannabis beverages market. The continued deregulation of cannabis, escalating societal acceptance, growing awareness of CBD benefits, and availability in familiar/popular formats are some factors supporting growth in demand and sales of cannabis beverages.

The CBD-infused beverages are gaining popularity in the US where they are becoming easily available through mainstream retail outlets. The growing interest in wellness drinks is also likely to drive gains in the market. Customers are increasingly demonstrating preference for wellness drinks over soft drinks, which is driving demand for cannabis beverages.

The market is also benefitting from other factors such as better living standards, increasing disposable income levels, and legalization of recreational cannabis in several countries. Off-trade channels such as lounges, clubs, restaurants, cafes, and hotels are likely to augment the product’s visibility and popularity among customers.

Non-Alcoholic, one of the segments analyzed in the report, is projected to grow at a 17.5% CAGR to reach US$1.6 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Alcoholic segment is readjusted to a revised 15.7% CAGR for the next 7-year period.

Non-alcoholic cannabis beverages dominate the market and are also expected to register strong growth, mainly supported by growing demand from female and new customers, especially millennials, and also rising interest in wellness drinks among customers. Cannabis-infused alcoholic beverages are also gaining strong popularity, given their capability to offer the alcohol effect, but with health advantages and no calories. They are mainly used by people who consume cannabis as well as alcohol.

The U.S. Market is Estimated at $752 Million in 2022, While Asia-Pacific is Forecast to Reach $146.7 Million by 2026

The Cannabis Beverages market in the U.S. is estimated at US$752 Million in the year 2022. The country currently accounts for a 70.9% share in the global market.

Asia-Pacific is forecast to reach an estimated market size of US$146.7 Million in the year 2026 trailing a CAGR of 14.2% through the analysis period. Among the other noteworthy geographic markets are Canada and Europe, each forecast to grow at 16.7% and 16.1% respectively over the analysis period.

North America is a dominant market, mainly driven by growth in the US market. Subsequent to the legalization of the use of hemp and its derived CBD products, sales of hCBD (hemp-cannabidiol) gained considerable impetus. Guam, Puerto Rico, the US Virgin Islands, District of Colombia, and 33 States have granted approval to medical cannabis programs (publicly available), which led to the introduction of many cannabis drinks.

Further, 13 states in the country permit the usage of high CBD and low THC products for medical uses, which has resulted in strong adoption of CBD infused cannabis drinks. Europe is another region that is likely to register surging demand, due to the growing interest in cannabis among consumers and the rising introduction of products. In developing regions such as Latin America, Oceania, and Asia, cannabis-based beverages have registered nominal growth due to the prohibition of THC products.

By Component, Tetrahydrocannabinol (THC) Segment to Reach 1.1 Billion by 2026

Demand for cannabis beverages infused with THC is being supported by the growing consumption among adult customers for recreational reasons. The euphoria they offer as well the therapeutic benefits are anticipated to foster their demand.

What’s New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies – Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to the digital archives
• Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Pandemic Leads to Increased Focus on Health and Wellness Products
• Pandemic Drives Consumer Shift towards Organic Foods
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
• An Introduction to Cannabis Beverages
• Global Market Prospects & Outlook
• Key Trends Influencing the Market
• Analysis by Type
• Analysis by Component
• Percentage Breakdown of Value Sales for Tetrahydrocannabinol (THC), and Cannabidiol (CBD)
• Regional Analysis
• Cannabis Beverages to Take the US Market by Storm
• Low-dose Cannabis Emerge as Alcohol Alternatives in Canada
• Competitive Scenario: Major Players Eying a Pie of the Cannabis Market
• Recent Market Activity

2. FOCUS ON SELECT PLAYERS (Total 79 Featured)

• Alkaline88, LLC
• Aphria Inc.
• Aurora Cannabis Inc.
• CannTrust Holdings Inc.
• Canopy Growth Corporation
• Cronos Group Inc.
• Dixie Brands Inc.
• GW Pharmaceuticals plc
• HEXO Operations Inc.
• Keef Brands
• Organigram Holdings Inc.
• Tilray
• VCC Brands
• VIVO Cannabis Inc.

3. MARKET TRENDS & DRIVERS

• Cannabis-Infused Beverages to Reduce Alcohol Consumption among the Young
• Prevailing Trends Positively Influence the Market
• Alcoholic Beverage Companies Seek Role in the Market
• Growth Trend to Continue
• Legalisation & Decriminalization Augur Well
• Legalisation Drives Demand in North America
• A Note On Clean Label Cannabis
• A Review of Trends Influencing the Market
• Favorable Demographics Strengthen Market Prospects
• Urban Sprawl Encourages a Positive Tide
• Rising Health Awareness to Fuel Market Prospects
• Growing Adoption of Herbal Remedies Widens Prospects
• Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
• Production Challenges Abound for Cannabis Beverage Producers
• Production Process of Cannabis Beverages – The Many Challenges
• Long-Term Studies on Stability of Products Essential
• Production Innovation Accelerates Market Growth
• Safety Challenges with Hemp-infused Products

4. GLOBAL MARKET PERSPECTIVE

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/f38qfv

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Cannabis in the US” report has been added to ResearchAndMarkets.com’s offering.

This report analyses the market for cannabis in the US.

The Cannabis in USA market report offers a comprehensive guide to the size and shape of this emerging market opportunity at a national level. It provides the latest retail sales data (historic date range), allowing you to identify the key cannabinoid categories driving growth.

It outlines the regulatory, cultural and commercial context and offers strategic analysis of key factors influencing the market – legislative developments both current and future, economic/lifestyle influences, illicit consumption, product innovation, distribution and pricing trends. Forecasts to 2026 illustrate how the market is set to expand and change.

Why buy this report?

• Get a detailed picture of the Cannabis market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Key Topics Covered:

Executive Summary

Cannabis Background

Summary 1 History And Evolution Of Cannabis In The Us

• Country Insight
• Cannabis Legislation

Summary 2 Cannabis Legislation In The Us

• Cannabis Distribution
• Cannabis Taxation

Summary 3 Cannabis Taxation By State In The Us

• Cannabis Production

Summary 4 Cannabis Production In The Us

• Illicit Cannabis Market
• Market Indicators
• Market Data
• Sources
• Medical Cannabis
• Adult-Use Cannabis
• CBD

For more information about this report visit https://www.researchandmarkets.com/r/4vt3t0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

LAS VEGAS–(BUSINESS WIRE)–Flower One Holdings Inc. (“Flower One” or the “Company”) (CSE: FONE) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today announced that its common stock listed on the OTCQB market, will be transitioned to the OTC Expert Market effective September 16, 2022, upon market open (the “Transition”). The Transition was a result of the Company no longer being considered a Foreign Private Issuer, and not being eligible for public quotation under Rule 15c2-11. The Company maintains its common share listing on the Canadian Securities Exchange and Frankfurt Stock Exchange.

About Flower One Holdings Inc.

Flower One is the largest cannabis cultivator, producer, and full-service brand fulfillment partner in the state of Nevada. By combining more than 20 years of greenhouse operational excellence with best-in-class cannabis operators, Flower One offers consistent, reliable, and scalable fulfillment to a growing number of industry-leading cannabis brands (Cookies, Kiva, Old Pal, Heavy Hitters, Lift Ticket’s, HUXTON, and Flower One’s leading in-house brand, NLVO, and more). Flower One currently produces a wide range of products from flower, full-spectrum oils, and distillates to finished consumer packaged goods, including a variety of: pre-rolls, concentrates, edibles, topicals, and more for top-performing brands in cannabis. Flower One’s Nevada footprint includes the Company’s flagship facility, a 400,000 square-foot high-tech greenhouse and 55,000 square-foot production facility, as well as a second site with a 25,000 square-foot indoor cultivation facility and commercial kitchen. Flower One has built an industry-leading team focused on making high-quality cannabis accessible to all.

The Company’s common shares are traded on the Canadian Securities Exchange under the Company’s symbol “FONE”, and on the Frankfurt Stock Exchange under the symbol “F11”. For more information, visit: https://flowerone.com.

Cautionary Note Regarding Forward-Looking Information

Statements in this press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of United States securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future actual results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or other similar expressions to be uncertain and forward-looking.

Forward-looking statements may include, without limitation, statements relating to the Company’s position as a leader in the Nevada cannabis market; the Company’s leadership as a cannabis cultivator, producer, innovator and full-service brand fulfillment partner; and the production of a wide range of products for the nation’s top-performing brands.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement, the “Cautionary Statement regarding Forward-Looking Information” section contained the Company’s management’s discussion and analysis for the three and twelve months ended December 31, 2021 (the “MD&A”). All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company’s public securities filings with the Canadian securities commissions, including the Company’s MD&A. Although Flower One has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended.

Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this press release are made as of the date of this release. Flower One disclaims and does not undertake any intention or obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contacts

Flower One Investor Relations

ir@flowerone.com

Kellen O’Keefe, President & CEO

702.660.7775

Flower One Media

media@flowerone.com

DUBLIN–(BUSINESS WIRE)–The “Cannabis Production in Canada – Industry Market Research Report” report has been added to ResearchAndMarkets.com’s offering.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.

The Cannabis Production industry in Canada has blossomed over the five years to 2019 as a massive market was introduced into the industry, driving up revenue late during the period.

Since Health Canada opened up medicinal cannabis production to more players in 2013, the industry has grown continuously as operators invest in production capabilities to produce quality products. However, the legalization of recreational cannabis in 2018 has been the primary driver of the industry boom during the period.

The Cannabis Act was implemented in October 2018, but ever since its announcement in 2017, the industry has begun to shift and transform as it transitions into a full-blown consumer product industry. The medicinal marijuana market has been growing significantly during the period, particularly as it was the only legal cannabis market up until late 2018.

This has driven innovation and fomented investment into the industry from major operators. The industry is still nascent, adapting to a new environment as established operators explore new frontiers and unlicensed producers transitional into legality. Industry profitability is expected to improve over the five years to 2024 as operators enhance efficiency and revenue continues to grow.

The Cannabis Production industry in Canada includes all companies licensed by Health Canada to cultivate, produce and sell products containing marijuana for medical and recreational consumption. The value of medical marijuana grown privately and illegal purchases of cannabis products for recreational use are both excluded from this industry.

Table of Contents

About this Industry

• Industry Definition
• Main Activities
• Similar Industries
• Additional Resources

Industry at a Glance

Industry Performance

• Executive Summary
• Key External Drivers
• Current Performance
• Industry Outlook
• Industry Life Cycle

Products & Markets

• Supply Chain
• Products & Services
• Demand Determinants
• Major Markets
• International Trade
• Business Locations

Competitive Landscape

• Market Share Concentration
• Key Success Factors
• Cost Structure Benchmarks
• Basis of Competition
• Barriers to Entry
• Industry Globalization

Major Companies

• Tilray Inc.
• Canopy Growth Corporation

Operating Conditions

• Capital Intensity
• Technology & Systems
• Revenue Volatility
• Regulation & Policy
• Industry Assistance

Key Statistics

• Industry Data
• Annual Change
• Key Ratios

For more information about this report visit https://www.researchandmarkets.com/r/9s28vy

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

 New in-house startup incubator will create an ecosystem of brands and products that propel the startup community

SAN DIEGO–(BUSINESS WIRE)–Sēd Communications, a female-run, first-of-its-kind marketing agency founded by advertising and PR industry veteran Loretta Markevics, is proud to officially launch The Greenhouse, an in-house incubator within Sēd that invents brands and products to directly support the startup community. Brands created in The Greenhouse are also used as testing grounds for trying out new marketing innovations, tactics and technologies before they are recommended to the agency’s current startup clients.

“Through the addition of The Greenhouse within Sēd we are able to provide an ecosystem of support for the startup community beyond marketing services. The brands we are developing in The Greenhouse will benefit startups in a variety of ways, from creating platforms that give startups more visibility to potential customers, to helping startup companies recruit new talent or providing specialized access to wellness for founders,” says Loretta Markevics, Founder of Sēd Communications.

The plan for the Greenhouse is to launch one new brand per year and any profits to be invested back into marketing those brands. Sēd’s agency team supplies all marketing support for the Greenhouse brands and as the owners of the brands they launch, the agency will use Greenhouse brands as a testing ground to experiment with new marketing tactics, technologies, and approaches.

“I’ve always loved startup brands because they’re willing to take risks – but they have to be smart and can’t afford to make mistakes given the stage they’re in. The Greenhouse allows us to pressure-test emerging tactics and technologies on the brands we create, like the metaverse or AI, and see proven success before recommending that our current agency clients invest in them to market their own brands. When every dollar counts for startups and digital marketing tactics and algorithms change every other week, it is more valuable than ever to know something works before recommending our clients invest in a new or unproven marketing approach,” says Markevics.

The Farmers Finds

The first brand launched by The Greenhouse is The Farmers Finds, a subscription service that provides a platform for farmers market-born brands to expand beyond their local footprint. Launched in late 2021, The Farmers Finds has grown to more than 1,000 subscribers in under six months of operating in stealth mode.

The idea for The Farmers Finds was born while Markevics was traveling across the country from 2020 until 2021, living in growing startup cities. During more than a year on the road, she visited farmers markets all over the United States to get to know the communities she was visiting and to speak to founders like herself to gain some insights about startup food and wellness brands. She quickly found that the non-produce farmers market brands did not have a unifying platform to promote themselves. Markevics put her marketing agency to work to create one and Sēd test-launched the first subscription box to give these farmers-market-born startups national exposure.

“It’s been an absolute joy working with Farmers Finds. They are great communicators and clearly in it to support US, the small business suppliers. In six months, they have gotten our products into over one thousand new households across the country.” – Caleb Mangum, Nutty Novelties

“With the marketplace the way it is today and with digital changes that happen so quickly, it’s harder than ever to sell. As a small business owner, being a part of The Farmers Finds has been very rewarding. I am able to connect with customers from across the country with more speed and ease than I could develop on my own. I am passionate about supporting other small businesses like mine, and The Farmers Finds allows me to be associated with other high-quality purveyors to enrich consumers each month in a fun and easy way.” – Monica Cutillo-Cody, Farmstead 1868

Supercharging Startup Growth

As a young startup agency, Sēd is also proud to announce that it is currently supporting ten startup brands, doubling its growth year over year since launch. The agency has added brands across categories including beauty, wellness, technology, solar, healthcare, cannabis and nonalcoholic spirits.

The Sēd name and brand come from the premise of supercharging small seeds of ideas into high-yield, differentiated yellow seeds capable of exponential growth. In her previous life as an award-winning, C-suite PR and advertising executive for some of the biggest agencies in the world, Markevics frequently used startups as a source of inspiration or put them on her competitive watch list for clients and decided in September of 2020 to use her over twenty years of experience providing strategic counsel to big global legacy brands to help startup brands win against them.

About Sēd Communications/Loretta Markevics

Loretta Markevics is a marketing visionary triggering hypergrowth for startup brands as the founder of integrated marketing agency Sēd. Loretta is using her previous experience as a global PR and advertising agency C-suite executive providing strategic counsel to the biggest brands in the world, to help startup brands win against them. Sēd’s approach helps startups differentiate themselves through category eruption: a reordering of category leadership by redefining the codes and conventions that define it. An understanding of the vulnerabilities of big brands, a passion for the underdog, a reputation for bold marketing ideas, and an innovative spirit enables the agency to deliver against this promise.

Contacts

Brittany Eisenberg

brittany@sedcommunications.com

AUSTIN, Texas–(BUSINESS WIRE)–Texas Original, Texas’ leading medical cannabis provider, announced its first product specifically designed to help qualifying patients who suffer from insomnia, night terrors or restlessness as a result of various medical conditions. The Sweet Dreams sleep gummy will be available to the company’s state-leading patient network in October.

Sweet Dreams is the first Texas Original product to incorporate cannabinol (CBN), a minor cannabinoid known for its sedative properties. It is also Texas Original’s first gummy containing terpenes—active chemical compounds that provide therapeutic effects for patients. Months in the making, the Texas Original product team performed multiple rounds of development trials to ensure the gummy’s effects and efficacy meet the highest levels of quality and consistency patients expect from the company’s exemplary gummy products. The Texas-inspired dewberry-flavored gummies will be available in 30-count packages formulated with 5 mg of CBN, 10 mg of THC and targeted rest terpenes in each gummy.

“Sleep is the bedrock of our health. But for many, sleep is often disrupted or damaged by the effects of PTSD, cancer and other debilitating conditions,” said Morris Denton, CEO of Texas Original. “We want to make sure every patient who struggles with sleep has several high-quality, trusted medical cannabis options to rely on. Hundreds of our patients have told us they are sleeping better than ever due to the power of medical cannabis. We encourage all patients who struggle with sleep to talk to their doctors about the Sweet Dreams gummy.”

Like all Texas Original gummy products, Sweet Dreams gummies are crafted with nanoemulsion technology for a faster onset time to induce quicker symptom relief. Patients can expect to feel the initial treatment effects as soon as 15 minutes after consumption—which is up to eight times faster than alternative CBN products in Texas. Texas Original gummies are also vegan and use natural food coloring and dyes.

“Our medical cannabis is expertly cultivated, meticulously extracted and rigorously tested to ensure every product we package is of the highest quality and efficacy,” said Kelly Roland, president of Texas Original. “One of the most important tenets of our production process is consistency. Patients suffering from sleep-related symptoms can count on our products to be the same week after week—to make sure that every night’s sleep is a good night’s sleep. Our fast-acting Sweet Dreams formulation incorporates CBN and targeted rest terpenes, along with THC, to help accomplish that goal.”

With 12 pickup sites and two full-time retail locations throughout the state—the largest distribution network of any provider—Texas Original’s Sweet Dreams gummies will be conveniently available to patients on a daily or weekly basis. To learn whether you or a loved one qualifies for medical cannabis, visit www.texasoriginal.com/patients.

About Texas Original

Texas Original is the leading licensed medical cannabis producer in Texas, working alongside physicians to provide the highest quality cannabis medicine to patients and families seeking relief across the state. As fellow Texans, we are dedicated to representing the integrity of this great state with our commitment to quality, consistency and purity in every product we produce. We remain committed to advancing safe, legal access to this powerful medicine. Texas Original is headquartered in Austin, with delivery throughout the entire state. For more information, visit www.texasoriginal.com.

Contacts

For Media Inquiries Only:
Callie Neatherlin

media@texasoriginal.com
512-439-9720